Welcome to our dedicated page for EyePoint news (Ticker: EYPT), a resource for investors and traders seeking the latest updates and insights on EyePoint stock.
EyePoint, Inc. develops and commercializes therapeutics for serious retinal diseases as a clinical-stage biopharmaceutical company. Its lead product candidate, DURAVYU (vorolanib intravitreal insert), is an investigational sustained-delivery treatment that uses bioerodible Durasert E technology and is being studied for wet age-related macular degeneration and diabetic macular edema.
Recurring EyePoint news covers clinical program updates, financial results, FDA naming and product-status disclosures, manufacturing and commercial-readiness topics, investor presentations, and equity inducement grants under Nasdaq Listing Rule 5635(c)(4). Company updates also address cash resources, corporate development activity, and disclosures tied to its Nasdaq-listed common stock.
EyePoint (Nasdaq: EYPT) granted non-statutory stock options as inducement awards under Nasdaq Listing Rule 5635(c)(4) to six new employees totaling 143,000 shares.
The options were granted on February 13, 2026, at an exercise price of $12.94 (closing price that day), have a 10-year term, and vest over four years (25% after one year, then monthly).
EyePoint (Nasdaq: EYPT) announced that George O. Elston, EVP and CFO, will participate in a fireside chat at the Guggenheim Emerging Outlook: Biotech Summit 2026 on Thursday, February 12, 2026 at 11:00 AM ET. A live webcast and archived replay will be available via the company Investors website at www.eyepoint.bio.
EyePoint (Nasdaq: EYPT) granted non-statutory inducement stock options to three new employees to purchase an aggregate of 13,900 shares of common stock. The options were granted on January 15, 2026 with an exercise price of $15.84 per share (the January 15 closing price), a 10-year term, and vesting over 4 years (25% after one year, then monthly over three years). Grants were approved by the Compensation Committee and made under NASDAQ Listing Rule 5635(c)(4) as inducement awards, with vesting conditioned on continued service.
EyePoint (Nasdaq: EYPT) provided a corporate update outlining pivotal 2026 milestones for DURAVYU (vorolanib intravitreal insert).
Key points: completed enrollment of >900 patients across Phase 3 LUGANO (432 U.S. patients) and LUCIA (475 global patients); topline wet AMD Phase 3 data expected beginning in mid-2026; Phase 3 DME trials COMO and CAPRI plan first patient dosing in Q1 2026 (~240 patients each); DURAVYU registration batches are in production to support an expedited NDA; corporate cash of approximately $300M at Dec 31, 2025 and a completed public offering raising $172.5M, providing runway into Q4 2027.
EyePoint (Nasdaq: EYPT) announced that Jay S. Duker, M.D., President and CEO, will present at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco on Tuesday, January 13, 2026 at 7:30 a.m. PT / 10:30 a.m. ET.
A live webcast and an archived replay will be available via the Investors section of the company website at www.eyepoint.bio.
EyePoint (Nasdaq: EYPT) granted inducement non‑statutory stock options to nine new employees on December 15, 2025 under Nasdaq Listing Rule 5635(c)(4).
The company awarded options to purchase an aggregate of 137,000 shares at an exercise price of $16.40 per share (closing price on December 15, 2025). Options have a 10‑year term and vest over 4 years: 25% on the first anniversary and the remainder in equal monthly installments over the following three years, subject to continued service. Grants were approved by the Compensation Committee.
EyePoint (Nasdaq: EYPT) announced a positive recommendation from an independent Data Safety Monitoring Committee (DSMC) after its second scheduled review of the pivotal Phase 3 LUGANO and LUCIA trials for DURAVYU in wet age-related macular degeneration (wet AMD) on Nov 19, 2025.
The DSMC found no safety signals and recommended both trials continue with no protocol changes. Enrollment is complete with over 900 patients. As of the Sept 29, 2025 cutoff all patients reached Week 8 and ~25% received a Week 32 redosing. Topline 56-week LUGANO data are on track for mid-2026, with LUCIA to closely follow.
EyePoint Pharmaceuticals (Nasdaq: EYPT) granted non-statutory stock options as inducement awards under NASDAQ Listing Rule 5635(c)(4) to seven new employees totaling 31,000 shares.
The options were granted on November 14, 2025, carry an exercise price of $11.58 (closing price that day), have a 10-year term, and vest over four years with 25% vesting at the first anniversary and the remainder monthly over three years, subject to continued service.
EyePoint (Nasdaq: EYPT) reported Q3 2025 results and corporate updates on Nov 5, 2025. Key operational items include completed enrollment of Phase 3 LUGANO and LUCIA for DURAVYU in wet AMD with >900 patients randomized and readouts beginning mid-2026, and initiation of a pivotal Phase 3 DME program (COMO and CAPRI) with first dosing expected Q1 2026 and FDA alignment on a non-inferiority approval pathway.
Preclinical data show DURAVYU reduces IL-6 activity >50% via JAK-1 inhibition plus VEGF receptor blockade. A $172.5 million underwritten offering in October fully funds the DME program and, with existing cash, extends runway into Q4 2027.
Q3 financials: revenue $1.0M versus $10.5M year-ago, operating expenses $63.0M, net loss $59.7M, and cash/securities $204M as of Sept 30, 2025 (plus ~$162M net October proceeds).
EyePoint Pharmaceuticals (NASDAQ: EYPT) announced management will participate in three investor events in November 2025: a Guggenheim Healthcare Innovation fireside chat on Nov 10, 2025 at 10:30 a.m. ET, a Stifel 2025 Healthcare corporate presentation on Nov 12, 2025 at 10:40 a.m. ET, and Jefferies London investor 1x1 meetings on Nov 17, 2025.
A live webcast and archived replay of each presentation will be available via the Investors section of the company website at www.eyepointpharma.com.